DF Dent & Co. Inc. Has $15.89 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

DF Dent & Co. Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 72.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,815 shares of the life sciences company’s stock after selling 321,910 shares during the quarter. DF Dent & Co. Inc.’s holdings in Illumina were worth $15,886,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV boosted its position in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in Illumina in the second quarter valued at about $61,000. Private Trust Co. NA raised its position in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. bought a new position in Illumina during the second quarter worth about $63,000. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 0.8 %

Shares of NASDAQ ILMN opened at $141.09 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm’s 50-day moving average is $142.90 and its 200-day moving average is $126.66. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 EPS. Equities analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group upped their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Finally, Scotiabank cut their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.